Insights
Public-record research for people who run floors — FDA inspection patterns, citation themes, and what cameras already reveal.
- 8 min read
Eugia’s CCTV findings, in FDA’s own words
From Form 483 narratives to the CDER reading-room file and June 2026 OAI coverage: how investigators used the plant’s own cameras — and cited blind spots — at Sangareddy.
PharmaFDACCTVEugiaPublic record - 7 min read
Unannounced FDA inspections make “always on” the only strategy
FDA’s May 2025 expansion of surprise foreign inspections — built on India/China pilots — meets our dashboard data: VAI-heavy years and a corridor that lives on continuous readiness.
PharmaFDAUnannouncedIndia - 7 min read
FDA already treats plant cameras as a quality system
Across published India Form 483s, FDA cites firms not for lacking CCTV — but for footage that wasn’t recorded, got purged, had blind spots, or nobody was watching.
PharmaFDAGMPCameras - 6 min read
India’s FDA drug inspections are back at record highs
FY2024–25 matched the 2019 peak. Roughly 1 in 10 drug inspections ends OAI — and about half end VAI, the documented “fix this voluntarily” shot.
PharmaFDAInspectionsIndia - 6 min read
What FDA cites — and what a camera would actually see
Of 1,607 India drug citations, ~30% map to floor behavior: procedures not followed, cleaning, aseptic conduct, training. The #1 finding is paper vs reality.
PharmaGMPCFR 211Cameras - 5 min read
An OAI is a coin flip on a Warning Letter
51% of India OAI drug inspections drew a Warning Letter at the same FEI within 18 months — median lag 193 days. FY2025–26 are the heaviest WL years on record.
PharmaFDAWarning LettersOAI - 6 min read
Hyderabad is the epicenter of India’s FDA pressure
The Hyderabad corridor accounts for hundreds of drug inspections and a dense VAI cohort since FY2024 — plus a cluster of recent Warning Letters you can trace end-to-end.
PharmaHyderabadFDAIndia - 5 min read
Import refusals: the revenue number behind the 483
52,089 India-origin US refusals since 2001. 2025 was the all-time record — ~2.6× 2019 — including heavy drug & biologics volume from household names.
PharmaImportsFDARisk - 6 min read
What an OAI actually costs — stock, ANDAs, and remediation
Same-day BSE filings, multi-percent stock drops, frozen approvals, and remediation that can run 15–20% of a unit’s sales. Why plant heads treat cameras as board-level risk.
PharmaRiskRemediationFDA